Impact Biomedical says Zoar Limited filed Form F-4 for merger with Impact
Zoar Limited filed the registration statement on September 10, 2026, a step Impact called a major milestone toward closing its planned combination.
Impact Biomedical Inc. (NYSE: IBO) said on September 16, 2026 that Zoar Limited, referred to as PubCo, filed a Form F-4 registration statement with the SEC on Thursday, September 10, 2026, in connection with its previously announced business combination with Zoar Labs Limited, formerly Dr. Ashley's Bio Labs Limited.1 The filing includes Impact's preliminary proxy statement, and the F-4 is available on the SEC's website under the name "Zoar Limited."1
Impact's management described the filing as a major milestone in the path to closing1, the company said.
Completion of the deal and the listing of PubCo's ordinary shares still depend on several conditions. These include the SEC declaring the registration statement effective, Impact stockholders approving the transaction, NYSE American approving the listing of PubCo shares, and satisfaction or waiver of other conditions under the merger and share exchange agreement.1
Impact said the combined company that would emerge from the merger with Zoar is meant to focus on making and supplying active pharmaceutical ingredients and related intermediates for specialized treatment areas, according to the release.
Under the merger terms referenced in the filing, a definitive proxy statement/prospectus will be mailed to Impact stockholders as of a record date to be set by Impact's board for a vote on the business combination once the registration statement is declared effective.1
The release also noted that Zoar Limited describes itself as a global pharmaceutical company focused on developing and manufacturing active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services for pharmaceutical and biotechnology companies worldwide.1 Impact said it discovers, confirms, and patents science and technologies that can be developed into biopharmaceutical and consumer healthcare offerings through partnerships including licensing, co-development, and joint ventures.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.